August 27, 2025

Playing Dominos: How an Artificial Protein Emerges from Fitting Together Individual Components

Playing Dominos: How an Artificial Protein Emerges from Fitting Together Individual Components

Heidelberg scientists develop AI model for producing new molecular machines in a targeted way

The targeted engineering of artificial proteins with unique properties – that is possible with the assistance of a novel method developed by a research team led by Prof. Dr Dominik Niopek at the Institute of Pharmacy and Molecular Biotechnology (IPMB) of Heidelberg University. It centers around a new AI model. This allows for forecasting how two proteins have to be fitted together at the molecular level from individual parts – subunits – in order to engineer a functional, adjustable new protein. Called ProDomino, this open-source tool opens up many different possible applications in biotechnology and medicine.

The Protein Domain Insertion Optimizer, abbreviated as ProDomino, can forecast which protein domains – like domino tiles – have to be fitted together to engineer a merged protein with new properties. | © Jan Mathony, Benedict Wolf

At the cell level, proteins drive numerous vital processes such as gaining energy or increasing genetic material and are hence frequently called the “molecular machines” of the cells. They consist of interlinked subunits known as domains. “Like components of a technical machine these domains have specific functions. For example, they enable the proteins to recognize external signals such as light or temperature, or to catalyze chemical reactions with the assistance of proteins,” underlines Prof. Niopek, who heads the Pharmaceutical Biology department at the IPMB. Novel proteins frequently arise naturally through existing domains connecting up in new combinations. 

Inspired by these evolutionary innovation processes, Dominik Niopek and his team have developed an AI model on the artificial recombination of protein domains. Extensive and high-quality data sets are essential to develop and optimize these complex computer models. “Through the automated analysis of huge protein databases we were able to produce a tailored data set with over 100,000 proteins. It reflects the enormous variety of natural domain combinations and was the central foundation for training our AI model,” says Benedict Wolf, a doctoral candidate in Prof. Niopek’s team. The Protein Domain Insertion Optimizer, abbreviated as ProDomino, can forecast which protein domains – like domino tiles – have to be fitted together to engineer a merged protein with new properties.

With the aid of ProDomino, for example, protein sensors, which react to stimuli like light or chemical substances, can be combined with effector proteins to control cellular processes. Consequently, the Heidelberg scientists succeeded in coupling chemosensitive domains with the “genetic scissors” CRISPR-Cas, thereby generating artificial CRISPR-Cas variants. These hybrid proteins can be deliberately turned on or off and so could considerably increase the safety of modern genome editing procedures, explains Dr Jan Mathony, group leader in Prof. Niopek’s department. The researchers have successfully tested their AI model on different proteins and made the software available to scientists as an open-source tool. 

“Our AI model allows for producing artificial proteins not only more easily but also in a more targeted way than before. This opens up new opportunities for improving the precision of protein-based applications in biotechnology and medicine, or possibly developing completely new therapy approaches,” says Prof. Niopek.

This research study was funded by the European Research Council (ERC) of the European Union. The results have been published in the journal “Nature Methods”.

Original Publication

B. Wolf, P. Shehu, L. Brenker, A.L. von Bachmann, A.S. Kroell, N. Southern, S. Holderbach, J. Eigenmann, S. Aschenbrenner, J. Mathony, D. Niopek: Rational engineering of allosteric protein switches by in silico prediction of domain insertion sites. Nature Methods (2025)

Further information

Our latest News

discover more
European Biotech Act: bioRN brings Industry and Policymakers together

European Biotech Act: bioRN brings Industry and Policymakers together

How can Europe strengthen its global competitiveness in biotechnology? Heidelberg, July 7th: This question was at the heart of a high-level roundtable hosted by the bioRN Life Science Cluster with Member of the European Parliament Hildegard Bentele. Representatives from Ascendis Pharma, BD, PROGEN, Novaliq, BASF Agricultural Solutions, PEPperPRINT, Evotec and Isenbruck Bösl Hörschler joined the […]

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

NORTH CHICAGO, Ill., July 6, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 […]

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

It should be biofunctional – that is, it should replicate the natural cellular environment as closely as possible – and it should be printable: bioink. Achieving both of these properties at the same time is an enormous challenge that conventional biomaterials often fail to meet. Together with two partner companies, researchers at the NMI have now taken an important […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp